Philip Morris International Inc. (PM) Earnings Call Transcript & Summary

April 20, 2021

New York Stock Exchange US Consumer Staples Tobacco earnings 72 min

Earnings Call Speaker Segments

Nicholas Rolli

executive
#1

Good day, everyone, and thanks for being with us. We put out a press release earlier today with full details about how we performed in the first quarter of 2021. That release can be found at www.pmi.com, or through the PMI IR app. Near the end of today's webcast slides — which are available on the website — you'll find a glossary of terms, covering the definition of Reduced Risk Products, or RRPs, along with adjustments, other calculations, reconciliations to the most directly comparable US GAAP measures, and extra heated tobacco unit market share data. Except where noted, whenever we mention IQOS, we mean our IQOS heat-not-burn products. When we refer to smoke-free products, that means our RRPs. Also keep in mind that growth rates given on an organic basis reflect currency-neutral underlying results. Remarks today include forward-looking statements and projections of future results. I'd ask you to look at the forward-looking and cautionary statements disclosure in today's presentation and press release, which reviews the various factors that could cause actual results to differ materially from projections or forward-looking statements. Also, please take note of the additional forward-looking and cautionary statements related to COVID-19. At this point, I'm happy to introduce Emmanuel Babeau, our Chief Financial Officer. Emmanuel?

Emmanuel Babeau

executive
#2

Thanks, Nick, and hello everyone joining us. I trust all of you on this call are doing well and staying healthy. During 2021's first quarter, our company turned in a robust showing that surpassed what we had anticipated, posting an all-time quarterly high for adjusted diluted EPS at $1.57, even with the ongoing difficulties brought by the worldwide pandemic. What stood out most was IQOS continuing its impressive expansion, accounting for 13% of shipment volumes and 28% of net revenues, up from 21.7% during the same period a year earlier. We kept up a very solid rate of bringing adult smokers over, arriving at roughly 19.1 million total users, with 14 million of them having fully replaced cigarettes with IQOS. HTU shipment volumes rose 30% versus the equivalent quarter last year, setting record market shares across major IQOS markets, with 12 countries achieving double-digit national share and an overall share of 7.6% in IQOS markets outside the U.S. Our operating margins likewise came in well above the same quarter a year ago, and though timing factors gave them some artificial lift, most of that gain stems from solid underlying results. Taken together, the strong organic net revenue and adjusted diluted EPS growth mean we are lifting our full-year guidance. On the product side, we keep expanding our smoke-free range and observed promising momentum from new devices and consumables in various markets. We anticipate gaining further from innovation as 2021 unfolds. Now to the headline figures. Q1 net revenues rose 2.9% on an organic basis. That was a superb result given a prior-year comparison that was essentially pre-COVID, and it factors in better-than-expected HTU, IMS and shipment volumes, which produced 32% organic growth in RRP net revenue; we also experienced somewhat greater-than-anticipated pull forward of shipments, mainly cigarettes within the EU region, before Easter, and in Russia ahead of the April 1 discount ban. We recorded robust organic growth of 6.9% in net revenue per unit, fueled by IQOS carrying more weight in our sales mix along with pricing on both combustibles and RRPs. Combustible tobacco pricing contributed 2.7% of prior year combustible net revenues, mirroring solid pricing across numerous markets, partly offset by Indonesia. Without Indonesia, combustible pricing exceeded 4%. Our adjusted operating income margin rose by 580 basis points on an organic basis; that mirrors IQOS carrying more weight and greater profitability; the beneficial effect of pricing; productivity savings, including reduced device cost; lower commercial spend stemming from the pandemic; the favorable comparison in Eastern Europe and certain other timing factors. Along with a lower effective tax rate, our resulting adjusted diluted EPS of $1.57 amounts to 21.5% organic growth, an exceptionally strong result. We estimate that timing factors this quarter, such as the earlier shipment just mentioned and cost phasing, added roughly $0.08. One-time factors contributed an estimated additional $0.02; that brings me to the 2021 guidance. Although the pace and form of the worldwide rebound from the pandemic are still unclear, the robust commercial performance and fundamental momentum seen in the first quarter — especially from our IQOS business — prompt us to lift our guidance. Our outlook for organic growth in net revenue and EPS still takes into account a variety of possible outcomes. That range presumes that even if restrictions return or persist for an extended period, consumption will not fall back to the depressed level seen in Q2 2020. So far we have felt no impact from the present worldwide semiconductor shortage, yet the guidance factors in a modest effect on the supply of electronic devices to consumers; this remains a fluid situation that we are watching carefully, and wherever a constraint emerges, we plan to manage our inventories appropriately and give priority to device sales to other smokers who are new to the category. As for duty-free, a recovery in worldwide travel probably will trail the gains in in-country mobility. Our guidance keeps assuming no significant duty-free rebound during this year. We now anticipate organic net revenue growth of plus 5% to plus 7%, compared with the plus 4% to plus 7% we communicated earlier, along with organic adjusted diluted EPS growth of plus 11% to plus 13%, or plus 15% to plus 17% on a reported basis. IQOS's strength is the primary reason behind this revision. We now expect to deliver HTU shipment volume between 95 billion and 100 billion units, which sits in the upper half of the range we previously targeted for 2021. Because of the ongoing strong momentum across our markets, the need to maintain inventory duration, and preparations for the rollout of IQOS ILUMA, which uses a different consumable, we expect our full-year shipments to run slightly ahead of our IMS volumes. We have also lifted our assumption for organic adjusted OI margin expansion to roughly plus 200 basis points; that figure covers the expectation of heavier investment in the second half as our innovation and commercial activities accelerate. As laid out in this morning's press release, our other main assumptions are unchanged; this projected organic EPS growth, which includes an estimated favorable currency impact of about plus $0.20 at prevailing rates versus the plus $0.25 assumed earlier, translates into a raised adjusted diluted EPS range of $5.95 to $6, or $5. This guidance excludes any effect of share repurchases. Still, we remain on track to restart repurchases in the second half of the year, subject to Board approval. Turning to the second quarter, we now expect adjusted diluted EPS of $1.50 to $1.55, reflecting strong topline growth against a weak prior-year comparison, continued margin improvement, and a partial reversal of certain Q1 timing benefits. For the second half, assuming many of our key markets will have largely emerged from COVID restrictions, we expect continued robust top line growth; this includes the contribution of higher expected device shipments, which will result in less gross margin expansion compared with the first half. The improved outlook incorporates an assumption of around 590 basis points of organic adjusted OI margin expansion. Fresh product introductions, spending on distribution, and how productivities are phased in will matter too. We're also going to increase what we spend commercially to support RRP's future growth via portfolio and geographic expansion, which includes launches like IQOS ILUMA. Versus the first half, we expect roughly an extra $300 million to $400 million in commercial investment, so organic OI margin expansion should come in lower during H2 — yet on the whole, we still see a robust expansion of about 200 basis point for the year. Before we dig deeper into the results, I'd like to call out some favorable regulatory news from the quarter. Acceptance of smoke-free products' harm reduction potential keeps building momentum. Cases from this year so far include Uruguay reversing a long-standing ban on importing heated tobacco product, plus Lithuania incorporating the harm reduction principle into its tobacco control agenda. We're also aware of the latest report by an all-party parliamentary group of MPs in the UK urging the WHO to go back to the FCTC's founding principle — one that embraces harms reduction instead of today's prohibitionist position.

Emmanuel Babeau

executive
#3

In New Zealand, we're going through the content and specifics of the consultation paper that came out last week. The policy acknowledges how innovative products contribute to harm reduction, and at the same time it makes sure there are tight controls so young people can't get access; when it comes to the EU, we remain hopeful that revising the tobacco excise directive will bring about greater amortization in the push toward smoke-free product, factoring in the pertinent good practices and experience that member states have acquired in this area. Both here and globally, we keep backing a differentiated regulatory and fiscal framework grounded in relative risk to health. While there are still occasional moves or suggestions that leave out harm reduction goals, we believe evidence and science will ultimately guide policy, and we continue to see encouraging shifts in numerous regions. Now, back to our performance: total PMI shipment volumes for Q1 declined 3.7%, which reflects ongoing robust expansion in HTUs of 30%, totaling 21.7 billion units, driven by the EU region, Japan, Russia, Ukraine, and a promising debut from a newly launched Middle Eastern market. HTU shipment and IMS volumes were largely consistent for the quarter. Although COVID-19 measures continued in many parts of the globe, the overall drop in industry volume was fairly mild at 0.7%, and that figure included growth of more than 25% in heated tobacco, a segment where our share remains above 80%. Our cigarette volumes fell, and while that decline was not as sharp as what we saw in Q4 2020, it does mirror particular share pressures in some markets, which I will address later. For both the second quarter and the back half of the year, we anticipate improved trends in combustible share and volume. IQOS performed very well, and that drove heated tobacco units to account for 13% of all the volume we shipped in Q1. For comparison, the figure stood at 9.6% in the same quarter a year earlier, 11% for the full year 2020, 8% in 2019 and 5% in 2018. With IQOS keeping up its positive momentum, we still anticipate that share will rise as time goes on, acting as a strong engine behind growth in both revenue and margin. The mix of what we sell is shifting quickly, which keeps us on the path toward our goal of turning into a company that is majority smoke-free by 2025. In the quarter, smoke-free products represented 28% of our overall net revenue, up from 21.7% in Q1 2020. On this call, we're looking at IQOS devices making up roughly 6% of the $2.1 billion in RRP net revenue. That reflects existing users waiting longer before replacing their devices, since battery life and reliability keep getting better, along with lower device prices in some markets as we get ready for IQOS ILUMA. In Q1, net revenue grew 2.9% on an organic basis even though shipment volume fell 3.7%, and that shows the twin engine behind our topline. The first piece is pricing on combustible, plus pricing on HTU in certain markets, net of the lower device pricing I just mentioned. The second piece is the growing share of HTUs in our business, which carry higher net revenue per unit and keep delivering substantial growth. As was covered during Investor Day, this becomes a more and more potent force as the changes we're making pick up speed. Now let me walk through what fueled the margin improvement in Q1, beginning with gross margin, which grew 390 basis points organically. A number of levers are behind this, highlighted in green on the slide, among them the HTU mix effect within IQOS. In particular, the considerable work we've done on manufacturing and supply chain efficiency is paying off, and it more than cancels out the drag from falling combustible volumes, with roughly $150 million in gross productivity savings coming through in Q1. Although this is somewhat weighted toward the early part of 2021, it marks a solid beginning on the path toward our $1 billion goal for 2021 to 2023. Within these savings, our gross profit gain got a lift from improved absorption of manufacturing costs thanks to heavy production during the quarter, plus lower device costs, adding up to an impact of about plus $60 million. Alongside the gross margin increase, we saw strong SG&A efficiencies, with adjusted marketing, administration and research costs coming in 200 basis points lower as a share of net revenue on an organic basis. This reflects how we keep digitizing and streamlining the way the business is operated, including our IQOS commercial engine along with work methods that are more efficient. Against our '21-'23 target of $1 billion in gross SG&A savings — measured before inflation and reinvestments — we put in about $60 million. SG&A costs this quarter were also shaped by the pandemic, as certain projects slipped to later dates and ongoing restrictions held commercial and overhead costs down. Roughly $100 million of the organic improvement came from those items combined. Turning to combustible now, we still hold the top international portfolio by market share and brand strength, as discussed at Investor Day; that provides a powerful base for speeding up IQOS growth through our commercial infrastructure, industry know-how and capacity to reach other smokers where allowed. So it's essential that we protect our leadership through targeted investment while also generating returns via pricing and efficiency. Our cigarette share shortfall in Q1 stems from a mix of several elements. These include COVID's effect on social occasions, where Marlboro is overrepresented; border closures and less travel; and cases of downtrading and rivalry in the mid and low-price tiers in certain markets like the Philippines and parts of the EU region. That result doesn't match our aim of holding our cigarette share, net of cannibalization; we anticipate a robust sequential cigarette share rebound over the rest of the year, backed by portfolio initiatives and Marlboro's lasting strength, particularly as pandemic restrictions loosen. So we're targeting cigarette share to be roughly flat year-over-year across the next nine months, even with cannibalization. Gains from HTUs will layer on top of that. I'll now move to the South and Southeast Asia Region. Following a tough 2020, especially in Indonesia, the pressures we faced are now easing; over in Indonesia, the trends for volume are getting better, with growth in the double digits for hand-rolled kreteks, a category where we hold the leading market position, which is helping keep PMI share steady in the Tier 1 segment. And really, as industry volume bounces back, our goal is volume growth for our business in this country during 2021. The primary challenge in Indonesia continues to be pricing. New excise duty rates took effect on February 1, and although every major player has implemented some level of pricing, the pace of progress is still slow. Even with the harm done to government revenues, no meaningful step has been taken yet to create equal conditions between the Tier 1 segment and the below Tier 1 segment, which keeps expanding. Our hope remains that, in time, the government will tackle this matter. The Philippines has delivered strong results in recent years; during this quarter, additional industry pricing in H2 2020, a sluggish economic rebound and restrictions tied to the pandemic produced a market contraction in the double digits. The share we lost mirrors downtrading from the mid to low-price segment, while premium-priced Marlboro, which accounts for more than two-third of our volume, is gaining share. Despite such obstacles, we have measures in place to tackle the share erosion and are aiming for organic net revenue that is close to stable in 2021, even as the overall market stays weak.

Emmanuel Babeau

executive
#4

I'd also like to share that in Metro Manila, IQOS has gotten off to a promising beginning — after the full launch during Q3 2020, HEETS exited with a share of nearly 1%. Broadly speaking, this region turned in robust expansion before COVID. Even though it might not serve as a significant growth engine during 2021, we anticipate it will weigh on group results much less than was the case in 2020; our goal is for regional organic net revenue to remain at minimum flat across the coming nine months. Turning next to how IQOS has performed, our estimate puts IQOS users at 19.1 million as of March 31. That works out to roughly 1.5 million adult users gained since December, which extends the step-up seen in the second half of 2020. The faster shift we made toward digital and remote engagement throughout the pandemic, paired with robust momentum behind the IQOS brand, is delivering returns. We also estimate that among this 14 million total, 73% of adult smokers have made the switch to IQOS and quit smoking, while the remainder are at differing stages of conversion. These solid conversion rates notably mirror the growing prevalence of IQOS 3 DUO, which delivers a better user experience than earlier device versions. As we said at Investor Day, our aim is to reach an even greater conversion rate over time by bringing in innovation, for example IQOS ILUMA. This expansion in users once more mirrors broad momentum throughout all key IQOS geographies, among them the EU region, Japan and Russia; it likewise mirrors the strengthening of our offer and the segmentation of the category through new products and additional price points, on both sides of our original HTU offering. Within the EU region, HEETS first quarter share hit a record 5.7% of overall cigarette and HTU industry volume. Once adjusted for estimated trade inventory movements, that equates to 46% year-over-year. IMS growth alongside roughly 10% sequential IMS growth, which accounts for fewer selling days during the period. I'd also like to remind you about the sequential quarterly share dynamic, which can be skewed by seasonality in the combustible market as well as pandemic-related circumstances like border closure and other social restrictions. Since the region will probably reopen to some degree in Q2 and expand the total market, we anticipate continued strong underlying HTU growth, though share should be roughly in line with Q1. This outstanding performance takes in strong growth in Italy, exceeding 10% share, where the vast majority of user acquisition arrived organically as rising awareness and prominence of the product generate its own momentum. Germany and Poland likewise contributed strongly. We gained an additional 700,000 EU region IQOS users during the quarter, bringing the total to 5.9 million, which continues the recent strong performance. We keep witnessing remarkable progress in key cities throughout the EU region, with several examples shown on this slide. HTU share in Rome now approaches 20%. Warsaw and Lisbon hit 15%, Munich 8%, and London 5%. Though it's a smaller city, the progress in Vilnius at 36% share is likewise a global standout. Like we said during Investor Day, major cities serve as a solid gauge for how much national share growth is possible, and I'd point you as well to the appendix, where we lay out shares for the key EU market and the world's key cities. Russia kept delivering a robust showing, as our HTU share climbed 1.2 points, hitting a record 7.7%. Once you adjust for assumed trade inventory shifts, that works out to IMS growth of plus 35% versus a year earlier and roughly plus 8%-10% quarter over quarter after accounting for estimated consumer pantry loading. Sequential share gains keep coming for both our HEETS and Fiit lineup, with solid momentum behind the regular HEETS and super-premium HEETS creation variants. On top of that, LIL SOLID and Fiit consumable keep adding to user acquisition; across both Russia and Ukraine, most consumers buying a LIL device are smokers stepping into the smoke-free category for the very first time, and conversion levels are high, matching IQOS. That's a promising sign for our capacity to reach adult smokers in the medium and below price segments, for whom purchasing power can be an obstacle. Margins on midstream-priced HTUs like Fiit stay appealing next to cigarettes carrying the same price, and although Fiit's volume is still modest relative to our overall HTU volume in this market, given our sizable IQOS user base, we anticipate LIL will expand further in 2021. Given this momentum in Russia and Ukraine, we intend to bring LIL SOLID to more markets later in the year; in Japan, on a total tobacco basis, cigarillos included and adjusted for trade inventory shifts, our HTU brands' share rose 3 points against the same quarter a year ago and 0.7 points sequentially, reaching 20.8%. HEETS and Marlboro HeatSticks both gained market share after the October price increase, underscoring the strength of our price-tiered portfolio. We anticipate additional HTU volume growth in Japan through the rest of the year, supported by continued user acquisition. Looking at the second quarter specifically, we expect solid sequential IMS growth; we also expect the total tobacco market to recover as the elasticity impact of the sizable October price increase fades, including its effect on consumer pantry-loading. So while year-over-year share growth should still be strong, Q2 share might not capture this underlying sequential growth performance and could be broadly flat against Q1 on an adjusted basis including cigarillos; in Q1, the overall heated tobacco category accounted for more than 28% of the adjusted total Japanese tobacco market, with IQOS holding a high share of segment. IQOS HTUs also hit an offtake share of 26.1% in Tokyo, having crossed the 25% milestone in December. Beyond strong growth in existing markets, our smoke-free product keeps expanding geographically. This lets us offer access to better alternatives for an ever-growing number of adult smokers and, as we communicated at Investor Day, we aim to be in 100 markets by 2025. Following the introduction of IQOS across 12 additional countries during 2020, Aruba joined the list in Q1, and we brought out IQOS VEEV, our latest e-vapor offering, in Finland. That brings the overall count of countries selling PMI smoke-free products to 66, and more than 50% of those sit beyond the OECD. Commercialization of IQOS VEEV presses ahead, with first-quarter rollouts in Italy and, as noted earlier, Finland. This comes on the heels of the debut markets, New Zealand and the Czech Republic, during the second half of 2020. Preventing youth access stands among our top objectives across the entire product lineup, and our aim is for every electronic smoke-free device we sell to carry age verification technology by 2023. Testing of that technology alongside IQOS VEEV will happen in chosen markets during this year. IQOS VEEV sits in the premium tier, delivering an elevated experience, and as previously discussed, IQOS's commercial setup lets us roll out efficiently and at scale via a tailored route-to-market strategy. Turning to our other big 2021 innovation: the arrival of IQOS ILUMA, the following generation of IQOS, which we unveiled at Investor Day. Capitalizing on what IQOS 3 DUO achieved, we expect this straightforward, intuitive device to enable simpler switching and stronger condition among legal-age smokers through Smartcore internal induction heating technology.

Emmanuel Babeau

executive
#5

We're still getting ready to bring ILUMA to market in the year's second half. While we introduce both IQOS VEEV and IQOS ILUMA, we're making careful arrangements across manufacturing and supply chain operations so we can handle anticipated demand, along with outside pressures like the tight global semiconductor supply situation I brought up earlier. IQOS 3 DUO's continued momentum more than 2 years after it debuted shows that meaningful innovation can deliver a durable, favorable effect on growth, and this confidence is mirrored both in the 2023 HTU shipment volume target we announced recently and in the raised HTU goal for this year. Transformation sits at the foundation of how we perform in business and in sustainability. There aren't separate strategies for us — retiring cigarettes by substituting superior options like IQOS fuels our expansion and tackles the largest impact we have on society. The fresh transformation targets unveiled at Investor Day underscore our distinctive pledge to retire cigarettes, and those targets line up with the 27 Business Transformation Metrics given to stakeholders so they can gauge and confirm how quickly and how broadly we're advancing. Among these are our goal of turning into a company that is majority smoke-free by 2025, our objective of bringing smoke-free products to market in 100 markets, and generating no less than $1 billion in net revenue from products beyond nicotine as we expand into neighboring business areas that carry a net positive effect on society. Outstanding ESG results let us strengthen our sustainability leadership. It makes me proud to witness growing outside acknowledgment, for instance regarding our work toward a fully sustainable supply chain and our dedication to tackling gender inequality. Additionally, we recently released data tied to a zero deforestation manifesto, reinforcing our heightened ambition to protect forests throughout our whole value chain; we stay firmly dedicated to offering the greatest possible transparency on the crucial ESG and product impact dimensions of our company through integrated reporting, and on May 18 we put out our 2020 disclosure. We understand that EFG analysis can yield useful perspectives on elements that could substantially affect financial performance, thereby improving the information available for investment choices. To further boost the worth of investor engagement and help people grasp the considerable positive effect PMI's transformation may have on society, we intend to host a sustainability webcast in early June, following up on our recent Investor Day. Kindly remember to mark your calendars. In closing, 2021 has begun strongly for us and we look ahead with confidence notwithstanding ongoing uncertainty in the operating environment stemming from COVID. This is the identical closing slide I showed at Investor Day in February, since I think how we began 2021 illustrates every essential component of our longer-term path. By means of IQOS we're constructing a business possessing multiple levers to produce superior and sustainable growth throughout the coming year via better volume dynamics, outstanding topline growth, robust margin expansion and rapidly rising earnings. On top of that, each adult smoker making the switch to IQOS benefits our company, and it's plainly a plus for how we affect society and public health too; we handle this transformation carefully and responsibly on behalf of our stakeholders, with our sustainability materiality framework as our guide, so that our positive impact is maximized across our Tier 1 ESG and product areas. That matters for keeping our business sustainable, and for producing superior returns for shareholders across the long term. Our raised organic growth outlook for 2021 represents one more step along this path, and it also places us well on track toward hitting our 2023 financial and HTU shipment targets. Thank you. At this point I'd be glad to take your questions.

Vivien Azer

analyst
#6

Good morning.

Emmanuel Babeau

executive
#7

Good morning, Vivien.

Vivien Azer

analyst
#8

With all the news that broke in the U.S. yesterday, could you help me out on my first question by just giving us a baseline on how IQOS is categorized in your markets outside America when it comes to taxation of the tobacco product type? Thanks.

Emmanuel Babeau

executive
#9

Vivien, let me make sure I follow — what you're asking, I believe, is how our heat-not-burn product and offering gets classified relative to combustible cigarettes in the geographies where we operate outside the U.S. Is that right?

Vivien Azer

analyst
#10

That is right. Yes, go ahead.

Emmanuel Babeau

executive
#11

OK. I cannot really provide a single universal response, since how these things get categorized may vary market by market. What I'd note is that at present, the levying of excise duty on IQOS being handled differently across most markets indicates that it is indeed treated distinctly, meaning the product is already dealt with in its own way on this specific point, in recognition that it differs from combustible cigarettes in both nature and characteristics. Naturally, then, we'll encounter circumstances differing between individual markets. We definitely support regulatory measures that would make clearer still that heat-not-burn offerings are unmistakably distinct and represent a superior option compared with combustibles going forward. As I believe I said earlier, we observe rulemaking advancing favorably across nation after nation to reflect this, gave a handful of illustrations in what I said before, and anticipate this trend persisting. Thus, we foresee an increasing number of governments enacting rules to sharpen the distinction between heat-not-burn alongside other reduced risk products and combustible cigarettes, accompanied by varying regulatory frameworks. And, as you're aware, we advocate for a differentiated approach concerning two areas. First, regarding how we may communicate about these superior alternatives and superior products relative to the combustible cigarette. And second, naturally, regarding taxation, to guarantee there's an incentive driving smokers toward this superior option for the sake of their health.

Vivien Azer

analyst
#12

Sure, that's useful. Many thanks. Then for my next question, could you share how you'd assess the danger that additional nations might place a nicotine ceiling on combustible cigarettes? Thanks.

Emmanuel Babeau

executive
#13

As you correctly point out, Vivien, nothing like that exists in any market at present. Any such concept would clearly need to be examined across every angle. There could be several effects when it comes to illicit trade, when it comes to smoking behavior — actually consuming a greater amount of combustible product just to reach an equivalent nicotine dose, and naturally that carries harmful consequences. So honestly, at this point it's premature to judge if such a measure could carry the intended purpose. Regardless, it would need to be paired with highly effective awareness efforts, access to superior substitutes, and definitely beginning with heat-not-burn were we to proceed — and that ought to be seen as motivation for individuals to stop smoking or move over to that superior substitute, with heat-not-burn certainly being the leading option that might be viewed as a pleasant and fulfilling substitute for smokers seeking a better product. So the concept itself — and it isn't a new one, since the FDA had already raised it back in 2017. As far as I can tell, not much effort has gone into examining all the possible ramifications; in our view, substantial work would be required regarding the effects, and additional scientific evidence would need to be collected and reviewed on the matter. Either way, from our standpoint, it would need to be paired with highly effective awareness, access, and positioning it as a substitute for those who don't wish to quit but do wish to continue using nicotine.

Vivien Azer

analyst
#14

Understood. Thank you very much.

Emmanuel Babeau

executive
#15

You're welcome.

Owen Bennett

analyst
#16

Morning, Emmanuel. Trust you're doing okay?

Emmanuel Babeau

executive
#17

How's it going?

Owen Bennett

analyst
#18

Alright, thanks. I'd like to zero in on the extra commercial spending you're planning for the back half. Can you share a bit more detail on what's driving that? Is most of it going toward launching VEEV and ILUMA? And related to that, how many markets do you honestly think VEEV and ILUMA can reach by the end of the year? Thanks.

Emmanuel Babeau

executive
#19

Absolutely, Owen. Regarding the commercial spend, naturally, what we're looking at here is our realistic expectation that conditions around COVID will steadily get better across a large number of markets. So the general expectation is that once vaccinations roll out and the trend turns favorable beginning in the summer, a lot of markets will shift toward steady, incremental gains. As you're aware, COVID kept us fairly constrained on the commercial side for quite a while—really across the entire portfolio, though it hit our IQOS business first and hardest. So once markets start to reopen, we'll broadly get back to communicating again, to raising familiarity with IQOS; rebuilding awareness around IQOS is truly essential for growing that business, and naturally that will drive more commercial and marketing efforts. Beyond that, your point is spot on—this stretch will matter a great deal because of the ILUMA and VEEV rollouts. VEEV's launch has already gotten underway, and we anticipate several markets coming on board during the back half of the year. We're still pinning down the exact count; getting it right and keeping the proper focus is what matters to us. As for ILUMA, the key market should sit at the very top of the launch priority list. I won't name names at this point, but you should not assume that our key market for IQOS will be the one appearing at the front of that list. Naturally, we'll need to put dedicated money behind this to ensure that people who smoke, along with those already using reduced-risk products, get a clear picture of what ILUMA offers. They should see why it outperforms the IQOS 3 DUO, which will drive higher conversion rates and stronger devotion to what we sell. That means we have to spend well during the back half of the year. This explains the $300 million to $400 million figure we've referenced.

Owen Bennett

analyst
#20

I really appreciate that. That's quite useful.

Bonnie Herzog

analyst
#21

Hello. I was hoping to perhaps ask...

Emmanuel Babeau

executive
#22

Hello, Bonnie.

Bonnie Herzog

analyst
#23

…a follow-up — hello, another question regarding ILUMA. I'm simply attempting to grasp, as the rollout happens, how much extra growth should we anticipate? In other words, based on what you folks foresee internally, do you anticipate many existing or loyal IQOS customers moving up to this device? Do you expect many fresh customers joining the IQOS ecosystem? Also, given that you're launching this extensive lineup of consumables alongside ILUMA, how — ought we to presume there's a certain degree of added expenses tied to that, resulting in pressure on margins, or perhaps not, just attempting to consider how much this might contribute positively for you?

Emmanuel Babeau

executive
#24

Yes, certainly, Bonnie, glad to address those two items. So regarding ILUMA's effect, our general expectation is that ILUMA will be beneficial. Well, to start with, naturally, when it comes to bringing in and transforming new smokers, since you'll encounter products that feel more instinctive and simpler to operate, and we succeed in persuading with ILUMA those smokers whom we hadn't been able to persuade previously; so that's the initial factor. Next, naturally, we'll likewise see some IQOS users or users of other heat-not-burn tobacco items making the switch to ILUMA, as it truly is a robust product offering considerable advantages to the consumer; and finally, since we think that concerning loyalty and individuals completely embracing heat-not-burn routines and not reverting to cigarettes, the reality that it's an improved product will also contribute quite favorably. Thus we anticipate that individuals quitting and going back to cigarettes will be significantly reduced yet again, as it's far simpler to operate, it's a superior overall experience, and we believe it will genuinely deliver a strong effect on that front. So as you can observe, we anticipate multiple factors supporting this ILUMA innovation to further enhance our performance with IQOS worldwide. As for consumables and overall at launch, I'd say you ought to anticipate, as is always the case with a new product introduction, that you're presenting a product < >, not entirely refined regarding manufacturing efficiency. It's a novel product; initially, the quantities are modest; you've invested; it requires time to become completely optimized. So beyond the expense of introducing the product for marketing and commercial purposes, there will be a certain effect on gross margin initially, since it's a novel product, and there will be a gradual increase in the profitability of this novel product and in the consumable margin for this novel product. And naturally, that is factored into our guidance.

Bonnie Herzog

analyst
#25

All right, that's quite useful. Thanks. Next, I'd like to return to a few of the reports that surfaced yesterday about a possible limit on nicotine content in cigarettes here in the US; so my question, I suppose, is whether there's any way for you to speed up the US launch of IQOS, because my sense is that should such a nicotine cap ever be put in place, IQOS would hold a clear edge. So I'd appreciate it if you could address that; and after that, perhaps your most recent thinking on the possibility of bringing VEEV into the US market. Could that now be a more realistic prospect; and if it is, have you filed a PMTA, or will you? Thanks.

Emmanuel Babeau

executive
#26

On the second point, about VEEV, it is definitely our plan to file a PMTA at some point. We haven't filed one so far, and I can't give you a timeline right now for when we will, but yes, filing one at some point is definitely our plan; as for expanding the IQOS business, naturally, we'll do that alongside our partner, Altria. Keep in mind, we don't commercialize IQOS in the US. Commercialization rights for IQOS have been licensed to Altria. Let's avoid overreacting to what isn't even < > actual news, in my view it's a press piece from yesterday, so we shouldn't jump too quickly to a conclusion or assume that everything will transform overnight. My view is that it's merely a press piece. That said, we're certain the FDA has one unambiguous aim, namely to advance a harm reduction policy that relies on innovation and scientific evidence, and they wish to oversee that, the MRTP we were granted for IQOS 2.4 signals < > that they regard IQOS as a beneficial contribution and, in their own words, that it's fitting for advancing public health. So this means that with IQOS we have a part to play, and we think this FDA vision is one we can support and nurture and assist in developing through our innovation and through IQOS, and naturally, together with Altria, we'll ensure we do as much as possible there

Bonnie Herzog

analyst
#27

All right. Thank you, again.

Emmanuel Babeau

executive
#28

Thank you.

Adam Spielman

analyst
#29

Hello, good afternoon. There are two things I'd like to ask. The first concerns IQOS's share of the market. In those initial couple of years, growth was really strong when you compared 4Q with 3Q and 1Q with 4Q. After that, market share hits storms, and you're able to observe, for instance, on Slide 19 and Slide 21, that during 2Q and 3Q there was essentially no expansion in Japan, or only a slight bit, plus in the EU and Russia. So my question, I suppose, is whether we ought to anticipate that same kind of pattern during 2021. To put it differently, strong expansion in 4Q, and you've just had < > strong expansion in Q1; after which market share will remain fairly flat across the coming couple of quarters in your main markets.

Emmanuel Babeau

executive
#30

Hello, Adam. Well, one thing I'd say is certainly the factor — and I'm certain you're keeping it in mind — that must be factored in is, before anything else, that underlying seasonality exists across numerous markets, and it affects CC volume and consequently the denominator, which gets affected; so even when IQOS keeps expanding and heat-not-burn worldwide keeps expanding quite healthily, that ends up affecting the total market share. On top of that, COVID's effect on border closures, its effect on illicit, and some market that went untracked and appeared, which was mostly CC business — naturally, once again, altering the denominator — has been affecting market share. So during 2021 we expect a combination, we believe, still carrying COVID's effect, of this ordinary seasonality along with the particular effect tied to COVID. Now, our target is growth that is progressive overall, yet it's accurate that in particular markets, we might see, following a very powerful acceleration in a single quarter, for every one of these reasons, the quarter after that arriving with reduced growth or even flat — naturally, measured year-on-year, growth remains very powerful; but you understand that; it's on a sequential basis that market share potentially fails to expand at the same rate. Naturally, this doesn't mean that even sequentially volumes aren't expanding either < > it's possible to have volumes expanding too while market share stays flat; so I'd say market share needs to be viewed with a pinch of salt and ought to be assessed across a longer stretch of time for what it tells us to carry meaning < >.

Adam Spielman

analyst
#31

Thanks; that's quite useful. My follow-up concerns the EPS outlook you provide each quarter. What I'm really asking is whether it bothers you that folks may be starting to ignore it — and that how the market views your company has slipped out of your hands, so to speak. Let me unpack that a little further. Over the last 2 or 3 years, each time you issued a quarterly forecast, it was way off. Do you no longer have control over the situation — or at minimum, if you put out a certain EPS figure, I suspect the actual result lands 10% or 12% higher — yet it happened once more this quarter, and still the stock has barely moved. There could be other explanations, sure, but to me it appears the market is essentially shrugging off your quarterly EPS outlook. That strikes me as a rather risky spot for you to be in. So I'm curious: do you agree with that read, does it concern you, why didn't you — since you were going to wager more on new ships toward the close of the quarter — why wasn't the market informed, and how do you expect this pattern to unfold from here?

Emmanuel Babeau

executive
#32

Yes, Adam. So let me take up your challenge regarding guidance and what we actually deliver, and I'd point to 2 sources — 2 reasons, 2 drivers — behind why we frequently exceed the guidance. The first, which I consider a positive one, is that the strength of the IQOS business often catches us off guard; we forecast a certain level and it arrives even more robust, which explains part of the beat in this Q1; so we aim to give a fair estimate of what's achievable, and when results come in above that, we treat it as welcome news — though admittedly, our forecasting has been overly conservative. The second, which I trust everyone grasps, is that in the current climate, it's harder to foresee or predict anything given all the volatility, and yes, we've been caught out by developments we hadn't properly foreseen — perhaps spending we intended to make even in March that ultimately never happened, in terms of investment that we'll instead carry out later in the year, or shifts in the market we hadn't anticipated well. Once more, with the COVID impact generating plenty of anxiety, volatility, and honestly something of a roller coaster in how the trade behaves — and even customers stocking up their pantries. That's really the actual reason behind why we've exceeded our guidance on those few occasions. And when we find out early in the quarter that we're going to come in above it, I mean, we communicate that when it genuinely occurs at the quarter's end. I think we feel it turns evident at the point where we say we're going to — we notice that quite near to the communication, if you will. Now, regarding your challenge — or your question — about whether this means the market no longer follows you. Well, I don't believe that's the situation. I think everyone grasps the particularity of this COVID circumstance and accepts that volatility can exist, along with things we fail to anticipate properly. And then, you know, given the strength of IQOS, I think everyone is able to form a view on what we can deliver. I think as of today we are revising the guidance on the number of HeatSticks for the year toward 95 billion to 100 billion. I think, based on Q1, that's truly the best possible assumption we can make for all investors, shareholder analysts, and it genuinely mirrors our vision at that stage.

Adam Spielman

analyst
#33

All right, thanks. That was a hard one to ask. Appreciate it.

Emmanuel Babeau

executive
#34

Thanks to you.

Michael Lavery

analyst
#35

Good morning. Thank you.

Emmanuel Babeau

executive
#36

Hi, Michael.

Michael Lavery

analyst
#37

I'd like to revisit what you said regarding HeatSticks pricing and the way you've started to differentiate things a bit further there. If I caught that correctly, you mentioned that you're now operating at price points both above and below the ones you originally had. In Japan, clearly, we saw the HEETS launch with a lower price point brought in, but could you share a bit more detail on how you're going above where you've been on price? Also, are there additional new brands — a second or a third one? And how is that positioned, and if it's not too early, what are you seeing so far?

Emmanuel Babeau

executive
#38

Sure, Mike. Glad to do that. Regarding IQOS and its consumable, the pattern we're seeing is fairly typical for a consumer goods category that's starting to reach a certain level of maturity. Naturally, I say that with real caution, because this is still quite a young category — yet in certain places, Japan being one example, along with some other markets where our share hasn't reached double digits, a degree of maturing is underway. As a result, the consumer — the customer — will generally make choices shaped by how much they can spend, by the way they personally live, and by whatever they wish to enjoy or whatever they want to communicate about their own life, or her life, to those around them. He's going to want a different kind of positioning when it comes to what he uses. So when you're chasing innovation — look at what we did with the HEETS consumable — at the start you've got just one single reference. Pretty soon, though, you realize the market needs to be segmented. There's a group of consumers who'll be really eager for something even more intense. So they want a better consumable and they're willing to pay extra for it, which means higher expenses — that's exactly the situation with Marlboro HeatSticks over in Japan, or HEETS creation in Russia, where you keep the premium sitting below the hyper < > premium, if you like. At some stage, a mid-tier offering will be needed too—and likely, further down the road, a mid-tier minimum positioning—since other buyers will want a lesser overall experience that still delivers strong rewards compared with what they previously got from the same type of combustible product, and naturally at a cheaper price. So I believe we're simply carrying out the right commercial marketing work to ensure we meet all of our customers' expectations. This unfolds step by step, and it's already pertinent in every nation. Yet as an increasing number of countries begin to mature somewhat, it will grow more and more pertinent across additional markets going forward.

Michael Lavery

analyst
#39

Alright, that's quite useful context. Regarding what you called the mature Japan market, where you picked up 3 or 4 share points year-over-year, I just want to confirm I grasp a few of the dynamics at play. You provided the adjusted share, which naturally leaves out certain trade moves as well as cigarillos, and then the other share figure. Across the 5 quarters you present, that spread has gotten somewhat wider — roughly 1.3, 1.5, 1.6, 1.9, and then 2.6. Sadly, our visibility into cigarillos isn't great. Is growth in that segment alone the main factor, or should we also keep in mind some inventory build when modeling 2Q and afterward?

Emmanuel Babeau

executive
#40

No, Michael, inventory build is not a worry at all. As for the cigarillo level, keep in mind that's a distinct category. The tax benefit will be gone entirely next October, yet up to this point it remains a highly dynamic category in Japan. So what we're seeing there, as I mentioned, has come after the October excise duty hike and the price increase. Our IQOS business overall — both Marlboro HeatSticks and HEETS — responded very, very well, and we gained really strong market share at the close of 2020 in Q4. That carried into Q1, so we're reporting very positive and genuine market share growth across the last 2 quarters, and we're quite pleased with that.

Michael Lavery

analyst
#41

Okay, great. Thanks so much.

Emmanuel Babeau

executive
#42

Thank you.

Chris Growe

analyst
#43

Hi, good morning.

Emmanuel Babeau

executive
#44

Hi, Chris.

Chris Growe

analyst
#45

You've already taken some questions. There are just 2 quick ones I'd like to ask. Regarding IQOS, I was simply wondering — your market share growth in Russia and the EU has been really impressive. In those same markets, you keep expanding how much of the product is available. Do you have a ballpark figure for how broadly IQOS is actually distributed, let's say across the EU and Russia? Is there room to push distribution further in those places so more consumers can see it?

Emmanuel Babeau

executive
#46

Sure — as we've stated, Russia doesn't yet have complete coverage from us. Within the EU, there are several countries where we're present in the major cities, though not yet with substantial nationwide reach — not, I'd say, with a great deal of capillarity. I believe Yatsik < >, back at the Investor Day, pointed to the share we hold in key cities and noted that looking back, the share from a few years earlier serves as a solid signal of where the entire market can end up a few years later. So I'd say that's quite a strong sign that we're able, naturally, to achieve an even bigger share in key cities along with the country overall, and the reality that we've accomplished this in key cities means it's highly probable — provided we keep performing well — that we'll arrive at a comparable share across the whole country; naturally though, the journey doesn't stop there, since we simultaneously kept growing share in the major cities, making it a continuous improvement, so to speak. That, I believe, is how you ought to view it.

Chris Growe

analyst
#47

Alright, that's useful. Thanks. One more item regarding combustibles, where you've faced some share pressure once again in this quarter, and there are certain causes behind that; but I was simply wondering, when I consider commercial spending in the latter half of the year, I was thinking that with respect to IQOS and reduced risk products, do you have to direct additional funds, additional focus, whichever term fits, toward combustible cigarettes to try and prop up some of that market share erosion? I recognize part of this stems from IQOS doing well, but I'm just curious about how you view that, and whether there's any sort of shift in the competitive landscape you're noticing in combustibles.

Emmanuel Babeau

executive
#48

I mean, we are definitely observing competition that is fairly vigorous in combustible, since for a lot of them, they have only a small footprint in RRP. So they're attempting to safeguard and grow their business in that area, and particularly at times they're feeling pressure due to expansion in the heat-not-burn segment. Chris, we're simply reminding everyone that holding onto our leadership in CC is a total priority. We require this leadership so that we can guarantee we preserve the connection with the smoker we aim to convert, in order to keep the influence with the trade to deliver our RRP offering to customers, and naturally, for the financial resources it supplies so we can invest behind RRP, so you ought to expect us to keep investing in CC to sustain this market share; it's evident that, even though it won't be the bulk, there will be certain investment in the latter half on the CC business as we protect our business; and as we observe some of the markets where we've occasionally been severely impacted by the COVID and we discuss the social consumption that has been hurting < > Marlboro. Well, since we believe the world is returning to a more social existence in the latter half, that will likely be a moment to get back to ensuring we preserve and further reinforce the leadership on Marlboro, as an illustration.

Chris Growe

analyst
#49

All right, that's quite useful. I appreciate the details.

Emmanuel Babeau

executive
#50

Thanks.

Pamela Kaufman

analyst
#51

I'd like to circle back and get a clearer picture of your guidance and how the pacing works out for this year, in light of how strong the first quarter was and what you're expecting for Q2. Your EPS guidance suggests a slowdown from roughly mid 20% growth in the first half down to high-single-digit growth in the second half, and of course, you mentioned the additional incremental investments, but is anything else weighing on the second-half outlook? Because even after you account for that extra incremental spending, it still points to a pretty significant deceleration in growth. So I'm just trying to figure out what's behind the fact < >...

Emmanuel Babeau

executive
#52

Well, Pamela...

Pamela Kaufman

analyst
#53

How cautious could that guidance be?

Emmanuel Babeau

executive
#54

Glad to address that. So, I believe we made clear that the first-quarter margin benefited, naturally, from certain delays in SG&A spending, and we indicated that we would be far more aggressive during H2, along with that additional $300 million to $400 million of investment compared with the first half. Yet we also pointed out that gross margin has been — what I mean is, the gross margin result in Q1 is truly remarkable, and across the year we will produce a really robust outcome when it comes to gains in gross margin rate. However, we noted that Q1 was likewise lifted by a non-recurring item tied to manufacturing productivity, and so, since that will not repeat, we expect a moderation there. We will also confront — this relates to Bonnie's earlier question — certain effects stemming from the introduction of ILUMA and the ILUMA consumable, which will create pressure on gross margin owing to the launch itself and the period required for manufacturing productivity to ramp up, and additionally there will be several investments hitting gross margin through distribution during the second half. So, when you put together the reality that Q1 was exceptional for several reasons and the reality that there is a boost < > at the gross margin level in Q2, alongside some negatively affecting factors plus greater investment, that is what shapes the outlook for margin in the second half. Even so, as I mentioned, we will maintain a quite attractive margin improvement, though I am certain you already picked up on that.

Pamela Kaufman

analyst
#55

Thanks. And I wanted to ask as well about what we've learned from IQOS VEEV and how it has performed in the first market where you launched it. My understanding is that you're using the IQOS platform you already have to bring VEEV to market. So in what ways are you guiding consumers among the different products?

Emmanuel Babeau

executive
#56

Right. At this point, Pamela, we're at a really early stage — just a handful of markets, extremely preliminary. Customer response has been quite positive, and it shows that the experience beats what most traditional vaping offers. So we're gathering the data, we're going through the initial information that's coming in from those markets, and once we have a little more to share, we will. For now, given the small number of markets and the very low volume, the qualitative feedback we're receiving from those markets pleases us.

Pamela Kaufman

analyst
#57

Wonderful, thanks.

Gaurav Jain

analyst
#58

Hello, and thanks. Good morning to you, Emmanuel.

Emmanuel Babeau

executive
#59

Hello there, Gaurav.

Gaurav Jain

analyst
#60

Let's return to what people have been asking about earnings repeatedly exceeding expectations and results landing above guidance — in what way does that shape how you think about the size and scheduling of buybacks?

Emmanuel Babeau

executive
#61

Gaurav, my view is that this doesn't carry a significant effect. As we communicated before, we believe we're fully on schedule, assuming, naturally, that the board gives its approval for us to launch a share buyback during the year's second half, which is what we told everyone at the Investor Day. At this point, I doubt we're forming a plan around that consideration. Like I mentioned, my hope is that as the COVID headwind fades, our ability to predict quarterly guidance will improve going forward. Therefore, I don't view it as something that will persist.

Gaurav Jain

analyst
#62

Absolutely. Thanks. My next question — and I might be wrong about this — but from what I understand, roughly 6 grams of tobacco go into a portion of IQOS, whereas 16 grams are contained in a pack of cigarettes. So wouldn't that mean a pack of IQOS delivers less nicotine than a pack of cigarettes does, and that could be something that works in your favor in this nicotine caps discussion?

Emmanuel Babeau

executive
#63

No, Gaurav, that isn't necessarily true. In certain countries, at certain points, it does affect excise duty, since excise duty in a number of nations around the world is levied on tobacco weight — but tobacco weight won't directly determine how much nicotine you take in via IQOS use compared with combustible use.

Gaurav Jain

analyst
#64

All right. That's great, and many thanks.

Emmanuel Babeau

executive
#65

Thanks. I really appreciate it.

Nicholas Rolli

executive
#66

Well, thank you very much.

Emmanuel Babeau

executive
#67

Thank you.

Nicholas Rolli

executive
#68

That concludes our call today. Sorry, Emmanuel, unless you had a comment.

Emmanuel Babeau

executive
#69

No, no — I simply wanted to express appreciation to all of you for joining today's call, and we're eager to speak with you before long.

Nicholas Rolli

executive
#70

Thanks. Should anything else come up that you'd like to ask, the Investor Relations team is the group to reach out to. Thanks once more, and enjoy the rest of your day.

Emmanuel Babeau

executive
#71

Bye-bye. Bye, everybody.

Operator

operator
#72

Thanks very much, everyone, and that brings today's conference call to a close. You're free to hang up now.

Read the full transcript via the API

You're viewing the first half of this call. Get the complete Philip Morris International Inc. transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.

Get the API View API docs →

This call discussed

For developers and AI pipelines

Programmatic access to Philip Morris International Inc. earnings transcripts and 132,000+ others is available through the EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments, full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.

More tools for stock research

OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in Philip Morris International Inc. or any ticker on your watchlist.

StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.